DGX

EX-99.1

2 dgx093020268-kex991.htm

EX-99.1

Document

Exhibit 99.1

Quest Diagnostics Reports Third Quarter 2026 Financial Results;

Raises Revenue and EPS Guidance for Full Year 2026

•Third quarter revenues of $3.10 billion, up 10.0% from 2025, on strong organic revenue growth

•Third quarter reported diluted earnings per share ("EPS") of $2.78, up 28.7% from 2025; and adjusted diluted EPS of $3.00, up 15.4% from 2025

•Full year 2026 revenues now expected to be between $12.065 billion and $12.105 billion

•Full year 2026 reported diluted EPS now expected to be between $10.21 and $10.31; and adjusted diluted EPS expected to be between $11.25 and $11.35

SECAUCUS, N.J., October 22, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2026.

“We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI,” said Jim Davis, Chairman, CEO and President. “Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year.”

Recent Highlights:

•Announced the ability for iPhone and iPad users in the United States to conveniently purchase a tailored Quest laboratory test panel with over 50 biomarkers directly through the Apple Health app, available to the public later this year.

•Finalized a definitive agreement to acquire select outreach lab assets from a leading health system and long-time Co-Lab Solutions customer in the Northeastern U.S. Continued to advance our Co-Lab Solutions implementation and joint venture lab with Corewell Health in Michigan.

•Extended our AD-Detect® menu to include the FDA-cleared Roche Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test and launched a new AD-Detect test panel with pTau217, amyloid beta and APOE to help guide diagnosis and treatment decisions for Alzheimer’s disease.

•Advanced Project Nova from the design phase to the solutions-build phase and continue to expect to deploy Epic solutions in our first lab in the fall of 2027.

The company will hold its 2027 Investor Day on March 25, 2027, at the New York Stock Exchange. Additional information will be provided closer to the event.

1

Three Months Ended September 30,Nine Months Ended September 30,

20262025Change20262025Change

(dollars in millions, except per share data)

Reported:

Net revenues$3,097 $2,816 10.0 %$9,035 $8,229 9.8 %

Diagnostic Information Services revenues$3,035 $2,755 10.2 %$8,845 $8,043 10.0 %

Revenue per requisition(4.2)%(2.8)%

Requisition volume14.5 %12.9 %

Organic requisition volume14.4 %12.8 %

Operating income (a)$479 $386 24.2 %$1,337 $1,170 14.3 %

Operating income as a percentage of net revenues (a)15.5 %13.7 %1.8 %14.8 %14.2 %0.6 %

Net income attributable to Quest Diagnostics (a)$312 $245 27.6 %$884 $747 18.4 %

Diluted EPS (a)$2.78 $2.16 28.7 %$7.86 $6.57 19.6 %

Cash provided by operations $611 $563 8.8 %$1,486 $1,421 4.6 %

Capital expenditures$166 $144 15.0 %$418 $369 13.2 %

Adjusted (a):

Operating income$517 $458 13.0 %$1,466 $1,330 10.3 %

Operating income as a percentage of net revenues16.7 %16.3 %0.4 %16.2 %16.2 %— %

Net income attributable to Quest Diagnostics$338 $296 14.2 %$969 $845 14.7 %

Diluted EPS$3.00 $2.60 15.4 %$8.62 $7.43 16.0 %

(a)For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.

Updated Guidance for Full Year 2026

The company updates its full year 2026 guidance as follows:

Updated GuidancePrior Guidance

LowHighLowHigh

Net revenues$12.065 billion$12.105 billion$11.95 billion$12.05 billion

Net revenues increase9.3%9.7%8.3%9.2%

Reported diluted EPS$10.21$10.31$9.97$10.17

Adjusted diluted EPS$11.25$11.35$11.05$11.25

Cash provided by operationsApproximately $1.90 billionApproximately $1.80 billion

Capital expenditures  Approximately $550 millionApproximately $550 million

Note on Non-GAAP Financial Measures

As used in this press release the term “reported” refers to measures under accounting principles generally accepted in the United States (“GAAP”). The term “adjusted” refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments and other items.

Non-GAAP adjusted measures are pre

EX-99.1

2 dgx063020268-kex991.htm

EX-99.1

Document

Exhibit 99.1

Quest Diagnostics Reports Second Quarter 2026 Financial Results;

Raises Revenue and EPS Guidance for Full Year 2026

•Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth

•Second quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and adjusted diluted EPS of $3.12, up 19.1% from 2025

•Full year 2026 revenues now expected to be between $11.95 billion and $12.05 billion

•Full year 2026 reported diluted EPS now expected to be between $9.97 and $10.17; and adjusted diluted EPS expected to be between $11.05 and $11.25

SECAUCUS, N.J., July 23, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2026.

“Our robust top- and bottom-line growth in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights that illuminate paths for better health,” said Jim Davis, Chairman, CEO and President. “Revenues increased by over 10%, almost all from organic revenue growth across our physician, hospital and consumer channels, and adjusted diluted EPS grew over 19%. With strong growth and sustained demand for our diagnostic insights, we are again raising our full year guidance.”

Recent Highlights:

Serving Customers and Delivering Innovations

•Continued to advance our Co-Lab Solutions implementation and joint venture laboratory with Corewell Health in Michigan and developed new capabilities in kidney care through our collaboration with Fresenius Medical Care in the United States.

•Generated robust revenue growth through questhealth.com and our consumer, wearable and wellness partners.

•Grew revenues by double-digits in several areas of Advanced Diagnostics, including Quest AD-Detect® blood tests for Alzheimer’s disease and advanced cardiometabolic and endocrine tests, including liver fibrosis testing.

•Granted New York State approval for our Haystack MRD® test and became the largest reference lab to utilize Flatiron Health's OncoEMR® Molecular Profiling Integration (MPI) platform for select cancer tests, including Haystack MRD, starting with a pilot with American Oncology Network (AON).

Driving Operational Excellence

•In the lab, extended automation solutions to improve quality and productivity in cervical cancer screening and front-end specimen processing to additional labs.

•Outside the lab, launched IntelliDraw™ to guide clinical staff of our physician customers through specimen collection, to enhance quality and the service experience.

1

Three Months Ended June 30,Six Months Ended June 30,

20262025Change20262025Change

(dollars in millions, except per share data)

Reported:

Net revenues$3,043 $2,761 10.2 %$5,938 $5,413 9.7 %

Diagnostic Information Services revenues$2,978 $2,699 10.3 %$5,810 $5,288 9.9 %

Revenue per requisition(2.8)%(2.1)%

Requisition volume13.1 %12.0 %

Organic requisition volume13.0 %11.9 %

Operating income (a)$459 $438 4.6 %$858 $784 9.4 %

Operating income as a percentage of net revenues (a)15.1 %15.9 %(0.8)%14.4 %14.5 %(0.1)%

Net income attributable to Quest Diagnostics (a)$320 $282 13.4 %$572 $502 13.9 %

Diluted EPS (a)$2.84 $2.47 15.0 %$5.08 $4.41 15.2 %

Cash provided by operations $597 $544 9.7 %$875 $858 1.9 %

Capital expenditures$138 $108 27.0 %$252 $225 12.1 %

Adjusted (a):

Operating income$502 $466 7.8 %$949 $872 8.8 %

Operating income as a percentage of net revenues16.5 %16.9 %(0.4)%16.0 %16.1 %(0.1)%

Net income attributable to Quest Diagnostics$350 $298 17.3 %$631 $549 14.9 %

Diluted EPS$3.12 $2.62 19.1 %$5.62 $4.83 16.4 %

(a)For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.

Updated Guidance for Full Year 2026

The company updates its full year 2026 guidance as follows:

Updated GuidancePrior Guidance

LowHighLowHigh

Net revenues$11.95 billion$12.05 billion$11.78 billion$11.90 billion

Net revenues increase8.3%9.2%6.8%7.8%

Reported diluted EPS$9.97$10.17$9.58$9.78

Adjusted diluted EPS$11.05$11.25$10.63$10.83

Cash provided by operationsApproximately $1.80 billionApproximately $1.75 billion

Capital expenditures  Approximately $550 millionApproximately $550 million

Based on the favorable resolution of various tax contingencies in the second quarter, the full year adjusted effective tax rate is expected to be consistent with 2025.

Note on Non-GAAP Financial Measures

As used in this press release the term “reported” refers to measures under accounting principles generally accepted in the United States (“GAAP”). The term “adjusted” refers to non-GAAP operating performance measures that exclude special items such as res

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.ce06d217.1784386256.ac52fb37

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.